Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension

NCT06618521 | Completed

• 1 other identifier: P.T.REC/012/004254
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to investigate the effect of Pilates exercises versus circuit exercise training on blood pressure and lipids in gestational hypertensive women.

Conditions

Gestational Hypertension

Outcome Measures

Primary Outcomes (5)

• Measurement of mean arterial blood pressure

  Pregnant women will be seated in a relaxed position with the arm supported on a table. A cuff will be secured around the bicep without excessive tightness. The cuff will be inflated while observing the aneroid monitor until the pressure reaches 20-30 mmHg above the usual blood pressure. A stethoscope will be placed below the cuff at the elbow crease, and the cuff will be gradually deflated. Systolic pressure will be recorded at the first Korotkoff sound, and diastolic pressure will be recorded when the sounds disappear. Mean arterial blood pressure will be measured for each pregnant woman in the three groups before and after the treatment procedures using the equation: MAP = 1/3 (SBP) + 2/3 (DBP).

  12 weeks

• Assessment of serum triglycerides level

  It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube.

  12 weeks

• Assessment of serum total cholesterol level

  It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube.

  12 weeks

• Assessment of serum low-density lipoprotein (LDL) level

  It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube.

  12 weeks

• Assessment of serum high-density lipoprotein (HDL) level

  It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube.

  12 weeks

Secondary Outcomes (2)

• Assessment of level of stress and anxiety

  12 weeks

• Assessment of serum cortisol level

  12 weeks

Study Arms (3)

Anti-hypertensive drug

ACTIVE COMPARATOR

It consists of 23 pregnant women. They will take Anti-hypertensive drug (Methyldopa 250 mg according to physician instructions).

Drug: Anti-hypertensive drug (Methyldopa 250 mg)

Anti-hypertensive drug + Pilates exercise

EXPERIMENTAL

It consists of 23 pregnant women. They will be engaged in Pilates exercise for 40 minutes/day, 3 days/week, for 12 weeks, in addition to Anti-hypertensive drug (Methyldopa 250 mg according to physician instructions.

Drug: Anti-hypertensive drug (Methyldopa 250 mg); Other: Pilates exercise

Anti-hypertensive drug + Circuit exercise training

EXPERIMENTAL

It consists of 23 pregnant women. They will be engaged in a supervised circuit training exercises for 40 minutes/ day, 3 days/week, for 12 weeks, in addition to Anti-hypertensive drug (Methyldopa 250 mg according to physician instructions.

Drug: Anti-hypertensive drug (Methyldopa 250 mg); Other: Circuit exercise training

Interventions

Anti-hypertensive drug (Methyldopa 250 mg) DRUG

Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.

Also known as: Methyldopa 250 mg

Anti-hypertensive drug; Anti-hypertensive drug + Circuit exercise training; Anti-hypertensive drug + Pilates exercise

Pilates exercise OTHER

Each women in the second group will receive Mat Pilates training exercise for 40 minutes/ day, 3 days/week, for 12 weeks beginning 20 weeks' gestation. The Pilates exercise includes pelvic floor exercise, deep tummy strengthening, pelvic tilt, upper back stretch, the cat stretch, thigh stretch, the sword, sword arm, and wagging the tail.

Anti-hypertensive drug + Pilates exercise

Circuit exercise training OTHER

Each women in group C will receive circuit training exercises in form of single leg curl up and press, sumo squat and row to reverse fly stand for 40 minutes/ day, 3 days/ week, for 12 weeks beginning 20 weeks' gestation. The Circuit exercise training includes sumo squat, quadruped extension, row to reverse fly stand, and single leg curls up.

Anti-hypertensive drug + Circuit exercise training

Eligibility Criteria

• Age: 25 Years - 35 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• They will be diagnosed by obstetrician after 20 weeks' gestation as having blood pressure higher than 140/90 without any organ damage.
• Age will range from 25-35 years old .
• Body mass index (BMI) will range from 30-34.9 Kg/m².

You may not qualify if:

• Cardiac problems
• Cognitive problems
• Poorly controlled hypertension
• Diabetes mellitus
• Inflammatory stage of arthritis
• Osteoporosis

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Cairo University

Giza, Egypt

Location

MeSH Terms

Conditions

Hypertension, Pregnancy-Induced

Interventions

Antihypertensive Agents; Methyldopa; Exercise Movement Techniques; Circuit-Based Exercise

Condition Hierarchy (Ancestors)

Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Hypertension; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Cardiovascular Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses; Dihydroxyphenylalanine; Catecholamines; Amines; Organic Chemicals; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Phenylalanine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Tyrosine; Physical Therapy Modalities; Therapeutics; Physical Conditioning, Human; Exercise; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Officials

• Abeer Mohamed Eldeeb, PhD

  Professor, Cairo university

  STUDY CHAIR

• Doaa A. Osman, PhD

  Assistant Professor, Cairo University

  STUDY DIRECTOR

• Hossam E. Hussein, PhD

  Professor, Al-Azhar University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 26, 2024
• First Posted: October 1, 2024
• Study Start: September 30, 2024
• Primary Completion: September 30, 2025
• Study Completion: October 31, 2025
• Last Updated: December 19, 2025

Record last verified: 2025-12

Locations

EG (1)